International Journal of Hematology

, Volume 88, Issue 4, pp 409–417 | Cite as

Current and future perspectives on the TARGET system: the registration system for Glivec® established by the JSH

  • Masahiro Kizaki
  • Shinichiro Okamoto
  • Tetsuzo Tauchi
  • Hideo Tanaka
  • Mitsune Tanimoto
  • Koiti Inokuchi
  • Tohru Murayama
  • Yoshio Saburi
  • Masayuki Hino
  • Mitsuru Tsudo
  • Taizo Shimomura
  • Yasushi Isobe
  • and the TARGET Investigators
Original Article

Abstract

Since hematology is a highly specialized field, an individual physician may not have much direct treatment experience with a given disease. Therefore, the Japanese Society of Hematology (JSH) has discussed establishing a registry of hematologic disorders, in order to contribute to improving the quality of treatments and clinical outcomes in this field. As a first step, the Timely and Appropriate Registration System for GLIVEC Therapy (TARGET), a registration system for chronic myeloid leukemia (CML) patients treated with imatinib, was established in October 2003. We present the preliminary results of the first 4 years’ experience with this system. CML patients treated with imatinib in Japan were registered through the website and the patient’s clinical course, including parameters and events like imatinib dose, blood counts, adverse events, and efficacy were recorded in months 1, 3, 6, 9, and 12 and then every 6 months thereafter. By September 2007, 862 patients from 176 hospitals were registered. Follow-up period was 0–54 months, and 127 patients were followed-up for more than 36 months. Based on these cumulative data, present imatinib treatment trends were analyzed and safety and efficacy were compared with international trial data.

Keywords

Glivec® CML Registration TARGET IRIS study JSH 

Notes

Acknowledgments

The Hematological Disease Registration Committee members are grateful to the hematologists from around Japan for their cooperation with the TARGET system and registration of cases.

References

  1. 1.
    Cancer Incidence in Five Countries, vol VIII, Parkin DM, et al., eds. IARC Press, Lyon, 2002.Google Scholar
  2. 2.
    O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994–1004. doi:10.1056/NEJMoa022457.PubMedCrossRefGoogle Scholar
  3. 3.
    Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–17. doi:10.1056/NEJMoa062867.PubMedCrossRefGoogle Scholar
  4. 4.
    Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or intereferon α plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423–32. doi:10.1056/NEJMoa030513.PubMedCrossRefGoogle Scholar
  5. 5.
    Kerkela R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12:908–16. doi:10.1038/nm1446.PubMedCrossRefGoogle Scholar
  6. 6.
    Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038–42. doi:10.1056/NEJM200104053441402.PubMedCrossRefGoogle Scholar
  7. 7.
    Kantarjian HM, Talpatz M, Giles F, O’Brien S, Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med. 2006;145:913–23.PubMedGoogle Scholar
  8. 8.
    Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:867–80. doi:10.1126/science.1062538.CrossRefGoogle Scholar
  9. 9.
    Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354:2542–51. doi:10.1056/NEJMoa055104.PubMedCrossRefGoogle Scholar
  10. 10.
    Talpatz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531–41. doi:10.1056/NEJMoa055229.CrossRefGoogle Scholar
  11. 11.
    Quintas-Cardama A, Kantarjian H, Jones D, et al. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood. 2007;107:497–9. doi:10.1182/blood-2006-07-035493.CrossRefGoogle Scholar
  12. 12.
    Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2006 (Epub ahead of print).Google Scholar

Copyright information

© The Japanese Society of Hematology 2008

Authors and Affiliations

  • Masahiro Kizaki
    • 1
  • Shinichiro Okamoto
    • 2
  • Tetsuzo Tauchi
    • 3
  • Hideo Tanaka
    • 4
  • Mitsune Tanimoto
    • 5
  • Koiti Inokuchi
    • 6
  • Tohru Murayama
    • 7
  • Yoshio Saburi
    • 8
  • Masayuki Hino
    • 9
  • Mitsuru Tsudo
    • 10
  • Taizo Shimomura
    • 11
  • Yasushi Isobe
    • 12
  • and the TARGET Investigators
  1. 1.Department of Hematology, Saitama Medical CenterSaitama Medical UniversityKawagoeJapan
  2. 2.Division of HematologyKeio University School of MedicineTokyoJapan
  3. 3.First Department of Internal MedicineTokyo Medical UniversityTokyoJapan
  4. 4.Department of Hematology and Oncology, Research Institute for Radiation Biology and MedicineHiroshima UniversityHiroshimaJapan
  5. 5.Department of Hematology, Oncology and Respiratory MedicineOkayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesOkayamaJapan
  6. 6.Division of Hematology, Department of Internal MedicineNippon Medical SchoolTokyoJapan
  7. 7.Hematology Division, Department of MedicineHyogo Cancer CenterHyogoJapan
  8. 8.Department of HematologyOita Prefectural HospitalOitaJapan
  9. 9.Clinical Hematology and Clinical Diagnosis, Graduate School of MedicineOsaka City UniversityOsakaJapan
  10. 10.Department of HematologyOsaka Red Cross HospitalOsakaJapan
  11. 11.Department of HematologyNTT Japan Kyushu HospitalKumamotoJapan
  12. 12.Division of Hematology, Department of Internal MedicineJuntendo University School of MedicineTokyoJapan

Personalised recommendations